CU23587B7 - Composición farmacéutica de palonosetrón - Google Patents

Composición farmacéutica de palonosetrón

Info

Publication number
CU23587B7
CU23587B7 CU20050158A CU20050158A CU23587B7 CU 23587 B7 CU23587 B7 CU 23587B7 CU 20050158 A CU20050158 A CU 20050158A CU 20050158 A CU20050158 A CU 20050158A CU 23587 B7 CU23587 B7 CU 23587B7
Authority
CU
Cuba
Prior art keywords
palonosetrón
pharmaceutical composition
vomiting
invention offers
operative nausea
Prior art date
Application number
CU20050158A
Other languages
English (en)
Inventor
Alberto Macciocchi
Luigi Baroni
Ricardo Braglia
Enrico Braglia
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32908576&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU23587(B7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of CU23587B7 publication Critical patent/CU23587B7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)

Abstract

El presente invento ofrece métodos para tratar la náusea y vómito post operatorios, así como emesis en general, con antagonistas receptores 5-HT3. En particular, el invento ofrece los métodos para reducir la náusea y vómito post operatorios y otros eventos eméticos con palonosetrón.
CU20050158A 2003-02-18 2005-08-17 Composición farmacéutica de palonosetrón CU23587B7 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44834203P 2003-02-18 2003-02-18

Publications (1)

Publication Number Publication Date
CU23587B7 true CU23587B7 (es) 2010-10-30

Family

ID=32908576

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20050158A CU23587B7 (es) 2003-02-18 2005-08-17 Composición farmacéutica de palonosetrón

Country Status (31)

Country Link
US (1) US20060074101A1 (es)
EP (2) EP1596862B1 (es)
JP (1) JP2006517944A (es)
KR (1) KR101113087B1 (es)
CN (1) CN1750822A (es)
AT (1) ATE490774T1 (es)
AU (1) AU2004212704B2 (es)
BR (1) BRPI0407549A (es)
CA (1) CA2515946C (es)
CU (1) CU23587B7 (es)
CY (1) CY1111312T1 (es)
DE (1) DE602004030424D1 (es)
DK (1) DK1596862T3 (es)
EA (1) EA013836B1 (es)
EC (1) ECSP055970A (es)
ES (1) ES2357769T3 (es)
GE (1) GEP20104908B (es)
HR (1) HRP20050709A2 (es)
IS (1) IS7983A (es)
MX (1) MXPA05008757A (es)
MY (1) MY143789A (es)
NO (1) NO20054296L (es)
NZ (1) NZ541862A (es)
PL (1) PL378122A1 (es)
PT (1) PT1596862E (es)
SI (1) SI1596862T1 (es)
TW (1) TWI355936B (es)
UA (1) UA96254C2 (es)
UY (1) UY28193A1 (es)
WO (1) WO2004073714A1 (es)
ZA (1) ZA200506580B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003302072A1 (en) * 2002-11-15 2004-06-15 Helsinn Healthcare Sa Palonosetron for the treatment of chemotherapy-induced emesis
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
BRPI0707325A2 (pt) * 2006-01-27 2011-05-03 Eurand Inc formulação de dosagem de liberação multiparticulada e método para preparação da mesma
CA2640460C (en) * 2006-01-27 2015-05-26 Eurand, Inc Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids
ATE427742T1 (de) * 2006-10-24 2009-04-15 Helsinn Healthcare Sa Weichkapseln mit palonosetron-hydrochlorid mit verbesserter stabilitat und bioverfugbarkeit
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
US20090155363A1 (en) * 2007-12-14 2009-06-18 Todd Maibach Methods for oral administration of active drugs
JP5547065B2 (ja) 2008-05-15 2014-07-09 久光製薬株式会社 パロノセトロンを含有する経皮吸収製剤
EP2364138A2 (en) * 2008-12-08 2011-09-14 Teva Pharmaceutical Industries Ltd. Palonosetron formulation
HUE037300T2 (hu) 2009-05-20 2018-08-28 Inst Nat Sante Rech Med Szerotonin 5-HT3 receptor antagonisták lezionális vesztibuláris zavarok kezelésében való felhasználásra
ES2432618T3 (es) * 2009-05-20 2013-12-04 Inserm (Institut National De La Santé Et De La Recherche Medicale) Antagonistas del receptor 5-HT3 de serotonina para usar en el tratamiento o prevención de una patología del oído interno con déficit vestibular
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
EP2499137A1 (en) 2009-11-13 2012-09-19 Helsinn Healthcare S.A. Palonosetron metabolites
ES2623503T3 (es) * 2009-11-18 2017-07-11 Helsinn Healthcare Sa Composiciones para tratar náuseas y vómitos mediados centralmente
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
KR101368587B1 (ko) * 2010-12-27 2014-03-05 주식회사 삼양바이오팜 오심 또는 구토 방지용 조성물
US10071088B2 (en) 2012-06-26 2018-09-11 Precondit, Llc Anti-nausea drug combinations
JP2017504615A (ja) 2013-12-23 2017-02-09 サムヤン バイオファーマシューティカルズ コーポレイション パロノセトロンを含有する薬学組成物
MX384045B (es) 2016-04-14 2025-03-14 Sensorion (+)-azasetrón para su uso en el tratamiento de trastornos del oído.
JP6768404B2 (ja) * 2016-08-12 2020-10-14 武田テバファーマ株式会社 パロノセトロン又はその薬学的に許容される塩を含む医薬組成物
JP6705348B2 (ja) * 2016-09-23 2020-06-03 ニプロ株式会社 液体製剤、及び、パロノセトロンの安定性を向上する方法
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
KR101802183B1 (ko) * 2016-11-16 2017-11-28 주식회사 유영제약 팔로노세트론을 활성성분으로 함유하는 약제학적 조성물
GB201702250D0 (en) 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
SI3737378T1 (sl) * 2018-01-12 2023-06-30 Orion Corporation Kapljice palonosetrona za oči za zdravljenje ali preprečevanje slabosti in bruhanja
CN108703960A (zh) * 2018-07-25 2018-10-26 无锡鑫连鑫生物医药科技有限公司 一种帕洛诺司琼缓释微球及其制备方法和使用方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695578A (en) 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
US4937247A (en) 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
DE3650772T2 (de) 1985-04-27 2003-04-03 F. Hoffmann-La Roche Ag, Basel Derivate von Indazole-3-carboxamide und -3-carboxylsäure
GB8516083D0 (en) 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US5240954A (en) 1985-06-25 1993-08-31 Glaxo Group Limited Medicaments
US5578628A (en) 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
US4906755A (en) 1986-11-03 1990-03-06 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds
US4707484A (en) 1986-11-25 1987-11-17 Hoffmann-La Roche Inc. Substituted piperidinomethylindolone and cyclopent(b)indolone derivatives
US5011846A (en) 1988-02-23 1991-04-30 Merrell Dow Pharmaceuticals Inc. Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
US5344658A (en) * 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
PL166272B1 (pl) 1989-11-28 1995-04-28 Syntex Inc Sposób wytwarzania nowych addycyjnych soli z kwasami zwiazków trójpierscieniowych PL PL PL PL
US5189041A (en) 1990-11-16 1993-02-23 Syntex (U.S.A.) Inc. Tricyclic 5-ht3 receptor antagonists
US5137893A (en) 1991-03-07 1992-08-11 G. D. Searle & Co. Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
US5491148A (en) 1991-04-26 1996-02-13 Syntex (U.S.A.) Inc. Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
GB9305593D0 (en) 1993-03-18 1993-05-05 Smithkline Beecham Plc Pharmaceuticals
US5492914A (en) 1994-07-28 1996-02-20 Syntex (U.S.A.) Inc. 2-(1-azabicyclo[2.2.2]oct-3 s-yl)-6-hydroxy-2,4,5,6-tetrahydro-1H-benz[DE]is[2.2.2]oct-3's-yl)-6-hydroxy-2,3,3a,4,5,6-hexahydro-1h-benz [DE]isoquinolin-1-one and individual stereoisomers thereof
GB9423511D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB9423588D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB9625589D0 (en) * 1996-12-10 1997-01-29 Boots Co Plc Therapeutic agents
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US6294548B1 (en) 1998-05-04 2001-09-25 Hoffmann-La Roche Inc. Multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
AU4551499A (en) * 1998-06-08 1999-12-30 Advanced Medicine, Inc. Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5-HT3 receptors
WO2000024375A1 (en) * 1998-10-27 2000-05-04 Alcon Laboratories, Inc. Preservative system for topically administrable pharmaceutical compositions containing a fatty acid/amino acid soap
US6196963B1 (en) * 1999-03-02 2001-03-06 Medtronic Ave, Inc. Brachytherapy device assembly and method of use
WO2003100091A1 (en) * 2002-05-24 2003-12-04 Epidauros Biotechnologie Ag Means and methods for improved treatment using 'setrones'
AU2003302072A1 (en) * 2002-11-15 2004-06-15 Helsinn Healthcare Sa Palonosetron for the treatment of chemotherapy-induced emesis
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
US8598219B2 (en) * 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron

Also Published As

Publication number Publication date
EP2258367A3 (en) 2011-07-13
DK1596862T3 (da) 2011-03-28
GEP20104908B (en) 2010-03-10
JP2006517944A (ja) 2006-08-03
EP1596862B1 (en) 2010-12-08
TWI355936B (en) 2012-01-11
KR20050121671A (ko) 2005-12-27
CA2515946A1 (en) 2004-09-02
WO2004073714A1 (en) 2004-09-02
UY28193A1 (es) 2004-09-30
HK1076402A1 (en) 2006-01-20
EP1596862A1 (en) 2005-11-23
ES2357769T3 (es) 2011-04-29
EA200501318A1 (ru) 2006-02-24
PT1596862E (pt) 2011-03-15
KR101113087B1 (ko) 2012-02-15
AU2004212704B2 (en) 2009-10-01
AU2004212704A1 (en) 2004-09-02
BRPI0407549A (pt) 2006-02-14
HRP20050709A2 (en) 2005-12-31
ZA200506580B (en) 2006-06-28
DE602004030424D1 (de) 2011-01-20
ATE490774T1 (de) 2010-12-15
PL378122A1 (pl) 2006-03-06
NO20054296L (no) 2005-11-17
CY1111312T1 (el) 2015-08-05
US20060074101A1 (en) 2006-04-06
NZ541862A (en) 2008-04-30
MXPA05008757A (es) 2006-05-31
MY143789A (en) 2011-07-15
IS7983A (is) 2005-08-15
EA013836B1 (ru) 2010-08-30
EP2258367A2 (en) 2010-12-08
UA96254C2 (uk) 2011-10-25
ECSP055970A (es) 2006-01-16
CA2515946C (en) 2008-12-02
TW200418474A (en) 2004-10-01
NO20054296D0 (no) 2005-09-16
CN1750822A (zh) 2006-03-22
SI1596862T1 (sl) 2011-03-31

Similar Documents

Publication Publication Date Title
CU23587B7 (es) Composición farmacéutica de palonosetrón
UA95768C2 (ru) Антагонисты мускариновых рецепторов ацетилхолина
ECSP088971A (es) Ligandos 101 de los receptores nicotínicos de acetilcolina
ECSP066468A (es) Antagonistas de receptores muscarínicos de acetilcolina
NO20076347L (no) Nye regimer for orale monofasiske befruktningshindrene midler
NO20083630L (no) Nye pyridinderivater
CY1111767T1 (el) Υδρογονωμενα παραγωγα βενζο[c]θειοφαινιου ως ανοσορρυθμιστες
CL2007002167A1 (es) Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer.
ATE486079T1 (de) Azatricyclische verbindungen und deren verwendung
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
CL2007001710A1 (es) Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras.
BRPI0506777A (pt) antagonistas do receptor muscarìnico da acetilcolina
DE602005009977D1 (de) Tetralin- und indanderivate und deren anwendungen als 5-ht-antagonisten
SG148192A1 (en) Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents
ECSP066486A (es) Antagonistas de receptores de acetilcolina muscarínicos ii
CO2023013670A2 (es) Compuesto cristalino de antagonistas del receptor muscarínico de acetilcolina m1
DE50307717D1 (de) Opiod-rezeptor-antagonisten in transdermalen systemen mit buprenorphin
CR7949A (es) Metodo para el tratamiento post operatorio de nausea y vomito
EA200700949A1 (ru) Фармацевтические композиции, основанные на антагонистах nk2, для применения в педиатрической практике
BRPI0510407A (pt) derivados de 3-amino-2-fenilpirrolidina
UY29620A1 (es) Polimorfos de hidrocodona

Legal Events

Date Code Title Description
FG Grant of patent